[Molecular tumor board penile cancer-a challenge].
Molekulares Tumorboard Peniskarzinom – eine Herausforderung.
Biomarkers, tumor
COX2
Chemotherapy
Molecular targeted therapy
Neoplasm metastasis
Journal
Der Urologe. Ausg. A
ISSN: 1433-0563
Titre abrégé: Urologe A
Pays: Germany
ID NLM: 1304110
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
pubmed:
27
6
2019
medline:
31
7
2019
entrez:
27
6
2019
Statut:
ppublish
Résumé
Due to its low incidence there is only very limited data concerning molecular markers in penile cancer. Recent studies show potential prognostic markers for lymph node metastasis, survival and response to chemotherapy or targeted therapy. Nevertheless the number of patients in the studies is very limited. Therefor clear recommendations for clinical decisions remain very weak. Patients with metastatic disease should be treated in clinical trials with translational biomarker research to improve the molecular tumor board in the future.
Identifiants
pubmed: 31240374
doi: 10.1007/s00120-019-0973-7
pii: 10.1007/s00120-019-0973-7
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Review
Langues
ger
Pagination
774-780Références
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
pubmed: 17237035
Mod Pathol. 2007 Oct;20(10):1069-77
pubmed: 17690710
Virchows Arch. 2008 Apr;452(4):369-75
pubmed: 18305955
World J Urol. 2011 Jun;29(3):393-8
pubmed: 20602103
Virchows Arch. 2011 Feb;458(2):221-9
pubmed: 21085986
Hum Pathol. 2011 Aug;42(8):1078-88
pubmed: 21334718
J Urol. 2014 Apr;191(4):977-82
pubmed: 24262497
Virchows Arch. 2014 Apr;464(4):453-61
pubmed: 24535700
Eur Urol. 2015 Jan;67(1):142-150
pubmed: 25457021
J Urol. 2015 Sep;194(3):696-701
pubmed: 25801766
World J Urol. 2016 Mar;34(3):353-9
pubmed: 26026817
J Urol. 2016 Aug;196(2):570-8
pubmed: 26896570
Clin Genitourin Cancer. 2016 Oct;14(5):450-456.e1
pubmed: 26935231
Urol Oncol. 2016 Oct;34(10):433.e19-26
pubmed: 27381894
Eur Urol Focus. 2018 Jul;4(4):599-607
pubmed: 28753861
BJU Int. 2018 Mar;121(3):348-356
pubmed: 28921872
Eur Urol Oncol. 2019 Mar;2(2):214-221
pubmed: 31017099